Center for State Rx Drug Pricing

The Laura and John Arnold Foundation and Kaiser Permanente funded the = NASHP=20 Pharmacy Price Work Group during 2016 that delivered a set of new = state-based=20 policy approaches, and refined and reshaped other previously proposed = policies=20 intended to constrain pharmaceutical pricing. The set of policy = approaches=20 described in =E2=80=9CStates=20 and the Rising Costs of Pharmaceuticals: A Call to Action=E2=80=9D = has been well=20 received by states and stakeholders.

Our task now is to facilitate the next phase of work among states = wanting to=20 move forward with these different policies. We also need to build an = analytic=20 foundation for some of the more complex, but potentially more rewarding, = policy=20 approaches that are not yet ready for implementation.

Read More" class=3D"collapseomatic "=20 id=3D"id578">Read More

=20

To move the state agenda forward, the Laura and John Arnold = Foundation has=20 funded NASHP to establish the NASHP Center for State Drug Price Action. = The=20 Center is staffed by Jane Horvath, who brings expertise from work both = in the=20 pharmaceutical industry and the federal government, who will direct the=20 initiative, help promote it with states and support state-based=20 implementation. In brief, the Center will provide technical and = strategic=20 assistance to states, leverage legal and actuarial expertise for states = as=20 needed, distribute funding to a subset of states, and convene the Work = Group to=20 address policy and strategic issues that arise during this next phase of = the=20 project. The Center will also engage other state organizations to = advance the=20 states=E2=80=99 drug price policy agenda, and, lastly, disseminate = learnings =E2=80=93 successes=20 and challenges =E2=80=93 among states.

NASHP=E2=80=99s Pharmacy Costs Work = Group is=20 comprised of state leaders from governors=E2=80=99 staff, state = legislatures, Medicaid=20 programs, public employees, attorney generals=E2=80=99 offices, = state-based insurance=20 exchanges, comptrollers=E2=80=99 offices, and corrections departments. = The group aimed=20 to find new approaches to limit pharmaceutical costs by examining the = many=20 levers state governments have as policymakers, regulators, and = purchasers.

Susan Barrett, J.D., Executive Director, = Green=20 Mountain Care Board
Burl Beasley, D.Ph., MPH, MS = Pharm Clinical=20 Pharmacist, Oklahoma Health Care Authority
Robert Crittenden, M.D., Senior Policy = Advisor to=20 Governor, Washington
James = DeBenedetti Director, Plan=20 Management Division, Covered California
Rebekah = Gee, Secretary, Dept. of=20 Health and Hospitals, State of Louisiana
Rory Griffin, Deputy Director, = Arkansas Dept.=20 of Corrections
Richard = Gottfried, Chair,=20 Committee on Health, New York Assembly
Emily Hancock, RPH, Phar. D.,=20 MPA Clinical Pharmacist, Indiana Dept. of Social and Family=20 Services
Nathan Johnson, Chief = Policy=20 Officer, Washington State Health Care Authority
Heather = Korbulic, Executive=20 Director, Silver State Health Insurance Exchange
Kevin Lembo, Comptroller, = State of=20 Connecticut
Janet Mills, = J.D., Attorney=20 General, State of Maine
Rebecca = Pasternik-Ikard, Chief=20 Executive Officer, Oklahoma Health Care Authority
Sara Sadownik, Deputy Chief of = Staff,=20 Massachusetts Health Policy Commission
David Seltz, Executive = Director,=20 Massachusetts Health Care Commission
Norman Thurston, = Ph.D., Utah State=20 Legislature
Eileen Mallow, Deputy = Director, WI=20 Dept. of Employee Trust Funds
Linda Wiant, Chief, Medical = Assistance Plans,=20 State of Georgia
Josh Wojcik, Policy Director, = Connecticut=20 Office of the Comptroller
Trish Riley, Chair, Executive = Director,=20 NASHP

Please find information for all upcoming webinars of the Pharmacy = Cost Work=20 Group here, as well as the recordings and slide decks of previous = webinars:

=E2=80=A2 States=20 and the Rising Costs of Pharmaceuticals: A Call to Action, January 11th, = 2017

State policy makers interested in model legislation produced by this=20 workgroup may request access to a legislators guide and additional = background=20 materials. Please contact Corinne=20 Alberts if you wish to receive this state-only material.

For more information, please contact Jane=20 Horvath, staff lead for this project.

This Resource Center was made possible with support from Laura = and John=20 Arnold Foundation and produced by NASHP Pharmacy Costs Work=20 Group.

Latest Resources

Request for Proposals: State Drug Spending and = Pricing Policy=20 Initiatives

The National Academy for State Health Policy (NASHP), with support = from the=20 Laura and John Arnold Foundation, today launched the Center for State = Rx Drug=20 Pricing. Building on the work of the Pharmacy Costs Work Group, the = Center=20 will provide technical and strategic assistance to states, leverage = legal and=20 actuarial expertise as needed, distribute funding [=E2=80=A6]

June 20, 2017 | Filed under: Front Page-Rx, Pharmaceutical Costs, Prescription Drugs

Supreme Court Decision Removes Barrier to Importing = US Patented=20 Drug Products at Lower Cost

In its May 30, 2017 decision Impression Products, Inc. v Lexmark=20 International Inc., the Supreme Court ruled that patent law cannot be = used to=20 prevent the resale of products back into the United States. The Court = case=20 specifically concerned printer toner cartridges, but it is an = important ruling=20 in the context of the domestic policy [=E2=80=A6]

June 6, 2017 | Filed under: Blog Posts, Drug Pricing, Front Page, Front Page-Rx, Pharmaceutical Costs, State Health Policy Blog

State Wholesale Importation Program = Explained

Because the federal government has not been able to agree on an = approach to=20 constrain prescription drug prices, states need to address the = problem. Study=20 after study show how U.S. consumers pay the highest prices in the = world for=20 life-saving and life-enhancing drug treatments. The prices we pay may = fund the=20 research and development that [=E2=80=A6]

May 30, 2017 | Filed under: Drug Pricing, Front Page, Front Page-Rx, Pharmaceutical Costs, Prescription Drugs, Publications

Managing High Drug Prices through Importation: We Can = Get to=20 =E2=80=9CYES=E2=80=9D

There is growing public pressure to find an effective way to = address the=20 rising prices of prescription drugs. Multiple drug price bills await = action in=20 Congress and more than 80 bills have been introduced in state = legislatures in=20 2017. Among the variety of approaches aimed at managing drug prices,=20 importation from other countries is an [=E2=80=A6]

May 30, 2017 | Filed under: Drug Pricing, Front Page, Front Page-Rx, Pharmaceutical Costs, Prescription Drugs, State Health Policy Blog

Update: What=E2=80=99s New in State Drug Pricing = Legislation?

With 80 bills introduced in 2017, there is a high level of interest = in=20 pharmaceutical pricing among state legislators. However, despite = legislative=20 sessions wrapping up, very few laws have been enacted. To date, bills = have=20 passed in Maryland, Montana, New Mexico, New York, and Utah. In 2016, = Vermont=20 led the way with a price transparency [=E2=80=A6]

May 1, 2017 | Filed under: Blog Posts, Drug Pricing, Front Page, Front Page-Rx, Maryland, Montana, New Mexico, New York, Pharmaceutical Costs, State Health Policy Blog, Utah

Center for State Rx Drug Pricing

Featured Products

Pharmacy=20 Costs Work Group =E2=80=93 Model Legislation

States and the Rising Cost of Pharmaceuticals: A Call = to=20 Action

State Legislative Action on Pharmaceutical = Prices

Latest Resources

Request for Proposals: State Drug Spending and = Pricing Policy=20 Initiatives

Supreme Court Decision Removes Barrier to Importing = US Patented=20 Drug Products at Lower Cost

State Wholesale Importation Program = Explained

Managing High Drug Prices through Importation: We Can = Get to=20 =E2=80=9CYES=E2=80=9D

Update: What=E2=80=99s New in State Drug Pricing = Legislation?

For a full list of our Pharmaceutical Costs resources, click the Rx = Center's=20 logo below!

Portland, Maine Office:

Washington, DC Office: